Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rudin

Showing results (351-360 of 524) with videos related to

Pageof 53
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor ModelRupa Juthani, Brian Madajewski, Barney Yoo, et al.
Histopathology|January 5, 2026
Analysis of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1), DLL3, OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumoursJonathan Willner, Irfan Khan, Zeynep Tarcan, et al.
Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
JTO Clinical and Research Reports|January 5, 2022
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring <i>KRAS</i> MutationsKathryn C Arbour, Eusebio Manchado, Matthew J Bott, et al.
Nature Medicine|February 12, 2020
Regenerative lineages and immune-mediated pruning in lung cancer metastasisAshley M Laughney, Jing Hu, Nathaniel R Campbell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2023
Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 InactivationSoo-Ryum Yang, Erika Gedvilaite, Ryan Ptashkin, et al.
Cancer Cell|February 16, 2017
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 AxisEric E Gardner, Benjamin H Lok, Valentina E Schneeberger, et al.
EJNMMI Research|January 20, 2017
A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLCJohn P Crandall, Abdel K Tahari, Rosalyn A Juergens, et al.
Molecular Cancer|May 29, 2024
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studyMingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, et al.
JCO Precision Oncology|May 14, 2026
Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non-Small Cell Lung CancerN Ari Wijetunga, Nikhil P Mankuzhy, Emily S Lebow, et al.
Pageof 53

Showing results (351-360 of 524) with videos related to

Sort By:
Pageof 53
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor ModelRupa Juthani, Brian Madajewski, Barney Yoo, et al.
Histopathology|January 5, 2026
Analysis of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1), DLL3, OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumoursJonathan Willner, Irfan Khan, Zeynep Tarcan, et al.
Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
JTO Clinical and Research Reports|January 5, 2022
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring <i>KRAS</i> MutationsKathryn C Arbour, Eusebio Manchado, Matthew J Bott, et al.
Nature Medicine|February 12, 2020
Regenerative lineages and immune-mediated pruning in lung cancer metastasisAshley M Laughney, Jing Hu, Nathaniel R Campbell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2023
Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 InactivationSoo-Ryum Yang, Erika Gedvilaite, Ryan Ptashkin, et al.
Cancer Cell|February 16, 2017
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 AxisEric E Gardner, Benjamin H Lok, Valentina E Schneeberger, et al.
EJNMMI Research|January 20, 2017
A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLCJohn P Crandall, Abdel K Tahari, Rosalyn A Juergens, et al.
Molecular Cancer|May 29, 2024
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studyMingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, et al.
JCO Precision Oncology|May 14, 2026
Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non-Small Cell Lung CancerN Ari Wijetunga, Nikhil P Mankuzhy, Emily S Lebow, et al.
Pageof 53